# Imbruvica (ibrutinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ibrutinib

> The FDA approved Imbruvica (ibrutinib), sponsored by AbbVie Inc. (ABBV), on August 24, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Imbruvica (ibrutinib) |
| Codes | PCI-32765 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | Leukemia, Lymphocytic, Chronic, B-Cell, [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 16, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210563 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180216, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA210563 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20180216, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22

### April 21, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210563 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20200421, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20200421, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22

### December 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210563 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22

### August 24, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217003 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217003%22

### August 24, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210563 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA210563 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA210563 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-38 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-37 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22

### May 18, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210563 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20230518, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22
- openFDA Drugs@FDA: "NDA205552 SUPPL-40 (Efficacy): submission_status AP, submission_status_date 20230518, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205552%22

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT01804686

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT01804686

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05963074 (A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05963074

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05963074 (A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05963074

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib) (MRK)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ibrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imbruvica (ibrutinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ibrutinib

```bibtex
@misc{secapidev_pdufa_ibrutinib_20261116,
  title        = {Imbruvica (ibrutinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ibrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ibrutinib_20261116","title":"Imbruvica (ibrutinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ibrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
